The evidence base synthesized here charts the maturation of PD-1/PD-L1 checkpoint inhibition, exemplified by cemiplimab, from a rescue therapy in advanced/metastatic disease into a durable, biomarker-guided standard across multiple treatment settings. In advanced non-small cell lung cancer, EMPOWER-Lung 1 establishes cemiplimab monotherapy as first-line treatment for PD-L1-high (≥50%, with greatest benefit at ≥90%) tumors lacking EGFR/ALK/ROS1 aberrations, delivering superior overall survival (26.1 vs 13.3 months), progression-free survival, and objective response rate versus platinum-doublet chemotherapy, with a more favorable severe-toxicity profile (18.3% vs 39.9% grade ≥3 treatment-related adverse events). Notably, this benefit extends even to patients with brain metastases (median OS 52.4 vs 20.7 months), reinforcing PD-L1 expression as the central predictive biomarker guiding patient selection and expected magnitude of benefit, and positioning checkpoint blockade as a viable alternative to chemotherapy even in traditionally difficult-to-treat CNS-involved disease.
A second major trajectory is the migration of PD-1 inhibition into the adjuvant, curative-intent setting, illustrated by the C-POST trial in high-risk cutaneous squamous-cell carcinoma (nodal features like extracapsular extension, or nonnodal features such as perineural invasion, locally recurrent tumors, or T4 disease). Following definitive surgical resection, adjuvant cemiplimab significantly improved disease-free survival (24-month rate 87.1% vs 64.1%) and reduced both locoregional and distant recurrence versus placebo, signaling a shift in immunotherapy's role from managing metastatic burden to preventing recurrence after local control—an important precedent for expanding checkpoint inhibitor use earlier in the disease continuum, with an acceptable trade-off in added grade ≥3 adverse events and discontinuation rates relative to placebo.
A parallel thread, exemplified by linvoseltamab in the LINKER-MM1 study of relapsed/refractory multiple myeloma, demonstrates the broader immunotherapeutic trend toward bispecific/antibody-based agents achieving deep, durable responses (71% ORR, 52% complete response, 94% MRD-negativity) with survival endpoints not yet reached—paralleling the durability seen with checkpoint inhibition and underscoring a field-wide movement toward response depth (MRD, complete response) as outcome measures beyond traditional survival metrics, alongside consistent attention to demographic/subgroup modifiers (age, sex, race, treatment history) in evaluating generalizability and safety across trials.
Collectively, these relationships reflect a unifying macro-trend: immune-based therapies (checkpoint inhibitors and bispecifics) are being systematically repositioned across the cancer care continuum—from first-line metastatic treatment to adjuvant curative intent to relapsed/refractory settings—driven by biomarker stratification (PD-L1, MRD), validated in large randomized trials (EMPOWER-Lung 1, C-POST, LINKER-MM1), and consistently benchmarked against safety profiles relative to chemotherapy or placebo, marking a broader transition toward biomarker-directed, recurrence-prevention-oriented immunotherapy strategies.